2020. Status
Samson-Med is included in the list of strategic enterprises of Saint-Petersburg.
2019. The second stage construction and rebranding project.
Engineering system installation in the new manufacturing plant and finalisation of the rebranding process.
2017. The 80th Anniversary
Samson-Med celebrates its 80th anniversary. The new manufacturing plant construction process is in its active phase. Launch of numerous projects in R&D department on existing products and technologies modernization, partnerships with leading research institutes of Russian Federation.
2016. A project of strategic importance
Samson-Med becomes a resident of Saint-Petersburg Localization and Import Substitution Center. The project of the new Samson-Med manufacturing plant construction is recognized as strategic one for the city by the Saint-Petersburg Government.
2010. A new manufacturing plant and Pharmaceutical cluster
Samson-Med becomes a memeber of Saint-Petersburg Pharmaceutical cluster. An agreement on a new Samson-Med manufacturing plant construction signed by the Government of Saint-Petersburg.
1998. Launch of Samprost®
Registration and start of production of Samprost® which became one of the first locally produced biologic drugs against prostatitis.
1980s. Launch of peptide biologic drugs
Launch of peptide biologic drugs portfolio which were developed in collaboration with Saint-Petersburg Military-Medicine Academy: Thymalin® and Samprost®.
Samson-Med product portfolio contained more than 40 units at that time.
1975-1980. Launch of Cytochrome-C and infusional form drugs
The development of an injection form of Cytochrome C was completed together with the Leningrad Hematology and Transfusiology Research Institute. The production of infusion solutions was launched on the basis of the blood substitutes workshop. The workshop of blood substitutes and infusion solutions was considered an object of special purpose, since it produced drugs not only for the civilian population, but also “special orders” for the army: Aminopeptide, Hydrolysin, etc.
1970s. Launch of blood substitutes production
Launch of plasma-substituting drugs portfolio developed in collaboration with Hematology and Transfusiology research institute.
1963. Chymopsin and Chymotrypsin production
The company began production of Chymopsin and Chymotrypsin, which are still used in surgery and dentistry.
1941-1945. World War II
Samson-Med Company launches the production of penicillin and insulin, which are important for the military industry. The company was the first to introduce insulin production using ion-exchange resins. During the war, the territory of the plant had strategic importance: there was a line of defense, and the highest point of the plant was the observation and coordination center.
1937. Company Foundation
Samson-Med starts its history from enzyme manufacturing facility found in 1937 on the territory of meat processing plant. At the time of foundation, the company’s portfolio included basic endocrine-enzyme drugs: pepsin, hematogen, gastric acid.